A quantitative model‐based approach for adavosertib dose selection in patients with uterine serous carcinoma
The approach identifies risk factors that can aid in the decision to use a 250-mg monotherapy dose. This regimen may manage haematological toxicities across studies. A quantitative model-based approach predicts that reducing adavosertib doses minimizes risks, underscoring the need for dose adjustment.
Authors
- Kowser Miah (ORCID: https://orcid.org/0009-0003-4319-6728)
- Diansong Zhou (ORCID: https://orcid.org/0000-0002-2673-1069)
- Victoria de Giorgio‐Miller
- Didier Meulendijks (ORCID: https://orcid.org/0000-0002-4580-426X)
- Jincheng Yang
- Lynda Grinsted
- Damilola Olabode (ORCID: https://orcid.org/0000-0001-7675-5707)
- Karthick Vishwanathan (ORCID: https://orcid.org/0000-0002-6555-8131)
- Srinivas Bachina
- Dana Ghiorghiu
- Megan Gibbs (ORCID: https://orcid.org/0000-0002-7258-8187)
- George Kirk
- Shankar Lanke (ORCID: https://orcid.org/0000-0003-4221-6283)
Institutions
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Spain) (ES)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1002/bcp.70336
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca